New antibody treatment for Non-Hodgkin Lymphoma and a type of skin lymphoma
Biomarker Rich Clinical Trial of an Innovative Antibody Antagonist of TNFR2 in Non-Hodgkin Lymphoma Featuring Cutaneous T Cell Lymphoma (CTCL).
This project is testing a new antibody treatment, called BITR2101, for people with certain types of cancer, including Non-Hodgkin Lymphoma and Cutaneous T Cell Lymphoma.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston Immune Technologies and Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Winchester, United States) |
| Project ID | NIH-11131238 on NIH RePORTER |
What this research studies
This research focuses on developing a new antibody, BITR2101, designed to fight cancer by targeting a specific protein called TNFR2. This protein is found on cancer cells and also on cells in the surrounding tissue that help the cancer grow and resist treatment. By blocking TNFR2, this antibody aims to stop cancer growth and make other treatments more effective. Researchers hope this approach will be useful for several types of cancer, either alone or combined with other therapies.
Who could benefit from this research
Good fit: Patients with Non-Hodgkin Lymphoma, especially those with Cutaneous T Cell Lymphoma, might be ideal candidates for future studies related to this treatment.
Not a fit: Patients whose cancer does not express the TNFR2 protein or who have other cancer types not targeted by this specific mechanism may not receive benefit.
Why it matters
Potential benefit: If successful, this new antibody could offer a more effective way to treat Non-Hodgkin Lymphoma and Cutaneous T Cell Lymphoma by directly attacking cancer cells and their protective environment.
How similar studies have performed: This antibody, BITR2101, is described as the first and only one of its kind to dominantly shut down TNFR2 signaling, suggesting a novel approach.
Where this research is happening
Winchester, United States
- Boston Immune Technologies and Therapeutics, INC. — Winchester, United States (Active)
Researchers
- Principal investigator: Brooks, David G — Boston Immune Technologies and Therapeutics, INC.
- Study coordinator: Brooks, David G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.